Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Phillip G. Febbo net worth and biography

Phillip Febbo Biography and Net Worth

SVP of Illumina

Dr. Phillip G. Febbo M.D. serves as Senior Vice President, Chief Medical Officer of the Company. For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.

What is Phillip G. Febbo's net worth?: The estimated net worth of Phillip G. Febbo is at least $760,320.32 as of April 6th, 2022. Dr. Febbo owns 5,774 shares of Illumina stock worth more than $760,320 as of November 20th. This net worth evaluation does not reflect any other investments that Dr. Febbo may own. Learn More about Phillip G. Febbo's net worth.
How do I contact Phillip G. Febbo?: The corporate mailing address for Dr. Febbo and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Phillip G. Febbo's contact information.
Has Phillip G. Febbo been buying or selling shares of Illumina?: Phillip G. Febbo has not been actively trading shares of Illumina during the last ninety days. Most recently, Phillip G. Febbo sold 1,988 shares of the business's stock in a transaction on Wednesday, April 6th. The shares were sold at an average price of $360.01, for a transaction totalling $715,699.88. Following the completion of the sale, the senior vice president now directly owns 5,774 shares of the company's stock, valued at $2,078,697.74. Learn More on Phillip G. Febbo's trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Jacob Thaysen (CEO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 1 times. They purchased a total of 7,330 shares worth more than $991,675.70. The most recent insider tranaction occured on February, 22nd when CEO Jacob Thaysen bought 7,330 shares worth more than $991,675.70. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 2/22/2024.

Phillip G. Febbo Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/6/2022	Sell	1,988	$360.01	$715,699.88	5,774
11/8/2021	Sell	1,000	$406.83	$406,830.00
6/11/2021	Sell	1,000	$447.59	$447,590.00	5,151
4/16/2020	Sell	173	$300.00	$51,900.00	2,490
11/14/2019	Sell	155	$300.00	$46,500.00	1,506

Phillip G. Febbo Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $131.68

$129.72

$134.28

50 Day Range

MA: $140.18

$126.15

$155.15

2 Week Range

Now: $131.68

$93.51

$156.66

Volume

3,065,218 shs

Average Volume

2,121,208 shs

Market Capitalization

$20.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Financial Prophecy

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.